GW Phar­ma cannabi­noid to be test­ed for Alzheimer's ag­i­ta­tion; Acor­da rev­enue plum­mets as gener­ics evis­cer­ate its fran­chise

→ Alzheimer’s Re­search UK is fund­ing a study at King’s Col­lege us­ing GW Phar­ma’s re­cent­ly ap­proved cannabi­noid drug Sativex in de­men­tia. The study will fo­cus on Alzheimer’s pa­tients ex­hibit­ing signs of ag­gres­sion and ag­i­ta­tion.

Now that Eli Lil­ly has ac­quired Loxo in an $8 bil­lion buy­out, Loxo part­ner Bay­er is go­ing its own way on a pair of pro­grams. The phar­ma com­pa­ny re­port­ed Fri­day morn­ing that it ob­tained full rights for Vi­t­rakvi (larotrec­tinib) and BAY 2731954 (LOXO-195) un­der their change-of-con­trol clause. Bay­er now has ex­clu­sive mar­ket­ing rights in the US.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA